IBD Strong Peer2Peer for Self-Management of Psychological Distress

Sponsor
Jennifer Jones (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05722236
Collaborator
Crohn's and Colitis Canada (Other), Nova Scotia Health Authority (Other)
120
2
24

Study Details

Study Description

Brief Summary

Psychological distress (PD) as a result of inflammatory bowel disease (IBD) is prevalent and associated with worse disease-related outcomes. IBD-associated psychological distress (IBD-PD) is particularly common at initial diagnosis, during disease flares, before surgery, and during transitions of care. Access to evidence-based, gold-standard psychological interventions and emotional support for IBD-PD has been identified as a major care gap by persons living with IBD. The COVID-19 pandemic has further exacerbated the burden of PD for persons living with chronic diseases like IBD, predisposing at-risk individuals to even greater mental struggles. Studies have shown a minority of patients are asked about IBD-PD in routine clinical care and that even if asked, access to mental health care is extremely limited. iPeer2Peer is an evidence-based, peer-led, virtually administered intervention for IBD-PD in the pediatric population that has demonstrated feasibility, acceptability and early effectiveness. Using qualitative data derived from an extensive stakeholder engagement process, iPeer2Peer has been adapted to meet the needs of adults living with IBD-PD. This program, IBD Strong Peer, will be studied through a randomized, wait list-controlled hybrid implementation-effectiveness trial in Nova Scotia. This study will provide implementation data needed to improve and adapt the intervention and implementation strategy to meet local needs, as well as provide early effectiveness data. This data will inform the design and statistical power needed for future larger, multicenter randomized control trials. IBD Strong Peer has significant potential to improve access to evidence-informed interventions for IBD-PD.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: IBD Strong Peer2Peer
  • Other: Waitlist control
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
A Randomized, Wait List-Controlled, Clinical Trial of IBD Strong Peer for Self-Management of Psychological Distress by Persons Living With Inflammatory Bowel Diseases (IBD)
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Mar 1, 2024
Anticipated Study Completion Date :
Mar 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: IBD Strong Peer2Peer intervention

Behavioral: IBD Strong Peer2Peer
Mentee participants will experience the intervention: this group will partake in peer-led sessions (peer calls) consisting of up to 10 virtual sessions on Zoom lasting approximately 20-30 minutes in duration over eight weeks. Individual peer calls will be unstructured whereby trained mentors (patients with IBD who have undergone training to be a mentor) and mentees will be given the freedom to discuss whatever issues they choose. Psychological and emotional support is provided to the mentee by the mentor.

Other: Waitlist -controls

Other: Waitlist control
Wait list controls will be offered participation in the IBD Strong Peer2Peer intervention once post-control outcome measures have been completed.

Outcome Measures

Primary Outcome Measures

  1. Participant Satisfaction [week 4]

    Satisfaction, measured by the satisfaction questionnaire: QUOTE IBD, where QI index < 0.9 = suboptimal satisfaction)

  2. Participant Satisfaction [week 8]

    Satisfaction, measured by the satisfaction questionnaire: QUOTE IBD, where QI index < 0.9 = suboptimal satisfaction)

  3. Attrition rate [week 4]

    Rate of participants who drop out of the study

  4. Attrition rate [week 8]

    Rate of participants who drop out of the study

  5. Adherence rate [week 4]

    Rate of participants who adhere to the study protocol

  6. Adherence rate [week 8]

    Rate of participants who adhere to the study protocol

  7. Recruitment success [Pre-study Baseline]

    recruitment success [participation/ total number approached or referred]

  8. Recruitment success [week 4]

    recruitment success [participation/ total number approached or referred]

  9. Recruitment success [week 8]

    recruitment success [participation/ total number approached or referred]

  10. Fidelity [week 1]

    Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).

  11. Fidelity [week 2]

    Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).

  12. Fidelity [week 3]

    Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).

  13. Fidelity [week 4]

    Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).

  14. Fidelity [week 5]

    Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).

  15. Fidelity [week 6]

    Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).

  16. Fidelity [week 7]

    Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).

  17. Fidelity [week 8]

    Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).

  18. General quality of life score (Eq5D-3L ) [Pre-study Baseline]

    General quality of life score measured by the European Quality of Life 5 Dimensions 3 Level Version (Eq5D-3L) index

  19. General quality of life score (Eq5D-3L ) [week 4]

    General quality of life score measured by the European Quality of Life 5 Dimensions 3 Level Version (Eq5D-3L) index

  20. General quality of life score (Eq5D-3L ) [week 8]

    General quality of life score measured by the European Quality of Life 5 Dimensions 3 Level Version (Eq5D-3L) index

  21. General quality of life score (SF-36) [Pre-study baseline]

    General quality of life score measured by the SF-36 questionnaire

  22. General quality of life score (SF-36) [week 4]

    General quality of life score measured by the SF-36 questionnaire

  23. General quality of life score (SF-36) [week 8]

    General quality of life score measured by the SF-36 questionnaire

  24. IBD Related quality of life score [Pre-study baseline]

    IBD Related quality of life score, measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ)

  25. IBD Related quality of life score [week 4]

    IBD Related quality of life score, measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ)

  26. IBD Related quality of life score [week 8]

    IBD Related quality of life score, measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ)

  27. Participant Self efficacy score [Pre-study Baseline]

    Self-efficacy, measured by the New General Self Efficacy Scale

  28. Participant Self efficacy score [week 4]

    Self-efficacy, measured by the New General Self Efficacy Scale

  29. Participant Self efficacy score [week 8]

    Self-efficacy, measured by the New General Self Efficacy Scale

  30. Psychological distress (DSM-V) [Pre-study Baseline, week 4 and week 8]

    Participant psychological distress, measured by the DSM-V cross cutting questionnaire

  31. Psychological distress (DSM-V) [week 4]

    Participant psychological distress, measured by the DSM-V cross cutting questionnaire

  32. Psychological distress (DSM-V) [week 8]

    Participant psychological distress, measured by the DSM-V cross cutting questionnaire

  33. Psychological distress (PSS) [Pre-study Baseline]

    Participant psychological distress, measured by the Perceived Stress Scale (PSS)

  34. Psychological distress (PSS) [week 4]

    Participant psychological distress, measured by the Perceived Stress Scale (PSS)

  35. Psychological distress (PSS) [week 8]

    Participant psychological distress, measured by the Perceived Stress Scale (PSS)

  36. Psychological distress (GAD7) [Pre-study Baseline]

    Participant psychological distress, measured by the Generalized Anxiety Disorder Assessment (GAD7) scale

  37. Psychological distress (GAD7) [week 4]

    Participant psychological distress, measured by the Generalized Anxiety Disorder Assessment (GAD7) scale

  38. Psychological distress (GAD7) [week 8]

    Participant psychological distress, measured by the Generalized Anxiety Disorder Assessment (GAD7) scale

  39. Psychological distress (PHQ8) [Pre-study Baseline]

    Participant psychological distress, measured by the eight-item Patient Health Questionnaire depression (PHQ8) scale

  40. Psychological distress (PHQ8) [week 4]

    Participant psychological distress, measured by the eight-item Patient Health Questionnaire depression (PHQ8) scale

  41. Psychological distress (PHQ8) [week 8]

    Participant psychological distress, measured by the eight-item Patient Health Questionnaire depression (PHQ8) scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult IBD patient (18 years or older)

  • In a period of transition (newly diagnosed, transitioning from pediatric to adult care, flaring or changing medications, recently admitted to hospital, or facing the need for surgery)

Exclusion Criteria:
  • Screening positive for severe psychological pathology

  • Do not speak English

  • Diagnosis of a major comorbid psychiatric condition such as bipolar disorder or schizophrenia,

  • No access to the internet

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Jennifer Jones
  • Crohn's and Colitis Canada
  • Nova Scotia Health Authority

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jennifer Jones, Clinical Gastroenterologist, Associate Professor, Department of Medicine, Dalhousie University, Nova Scotia Health Authority
ClinicalTrials.gov Identifier:
NCT05722236
Other Study ID Numbers:
  • 50596
First Posted:
Feb 10, 2023
Last Update Posted:
Feb 10, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jennifer Jones, Clinical Gastroenterologist, Associate Professor, Department of Medicine, Dalhousie University, Nova Scotia Health Authority
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 10, 2023